EGM
ORMP icon

Engineers Gate Manager’s Oramed Pharmaceuticals ORMP Stock Holding History

Engineers Gate Manager’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,310
Closed -$299K – 1882
2021
Q2 		$299K Buy
+22,310
New +$255K 0.02% 1143

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
JC
Jetstream Capital Brentwood, Tennessee $1.37M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Engineers Gate Manager's ORMP Position: Q3 2021 in Review

Engineers Gate Manager sold out of Oramed Pharmaceuticals (ORMP) in Q3 2021, closing a stake of 22,310 shares — an estimated $299K sold.

Engineers Gate Manager first reported a position in ORMP in Q2 2021 and held it in 1 quarter. The position peaked at $299K in Q2 2021. 93 funds tracked by Wall St. Rank hold ORMP as of Q3 2021.

  • Engineers Gate Manager reported no remaining Oramed Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Engineers Gate Manager sold 22,310 Oramed Pharmaceuticals shares in Q3 2021, an estimated $299K.
  • Engineers Gate Manager first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Engineers Gate Manager's Oramed Pharmaceuticals position peaked at $299K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2021.

Based on Engineers Gate Manager's 13F filing for Q3 2021, filed 15 Nov 2021.